Stage IIIB Breast Cancer Completed Phase 1 Trials for Cilengitide (DB11890)

IndicationStatusPhase
DBCOND0028549 (Stage IIIB Breast Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01276496Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by SurgeryTreatment